Mollie Leoni

CIK: 0002051106

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)13 (76.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (23.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KURA

Kura Oncology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

KURA
Kura Oncology, Inc.
Sep 29, 2026
Sale(S)
Direct
28.8K shares at avg. $10.75$310K
KURA
Kura Oncology, Inc.
Sep 28, 2026
Sale(S)
Direct
12.4K shares at avg. $10.50$131K
KURA
Kura Oncology, Inc.
Jun 18, 2026
Sale(S)
Direct
84.9K shares at avg. $9.82$834K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
951 shares at avg. $8.46$8K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
3.7K shares at avg. $8.46$31K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
2.2K shares at avg. $8.46$19K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
1.3K shares at avg. $8.46$11K
KURA
Kura Oncology, Inc.
Jan 2, 2026
Award(A)
Direct
50K shares-
KURA
Kura Oncology, Inc.
Nov 14, 2025
Sale(S)
Direct
15.5K shares at avg. $11.18$173K
KURA
Kura Oncology, Inc.
Nov 13, 2025
Award(A)
Direct
82.5K shares-
KURA
Kura Oncology, Inc.
Sep 29, 2025
Sale(S)
Direct
12.3K shares at avg. $8.94$110K
KURA
Kura Oncology, Inc.
Sep 27, 2025
Award(A)
Direct
82.5K shares-
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
2.3K shares at avg. $7.87$18K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
816 shares at avg. $7.87$6K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
1.4K shares at avg. $7.87$11K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
541 shares at avg. $7.87$4K
KURA
Kura Oncology, Inc.
Jan 2, 2025
Award(A)
Direct
46.3K shares-

		Type	Shares	Price		Ownership
Sep 29, 2026	KURA Kura Oncology, Inc.	Sale(S)	28,802	$10.75	$309,567	Direct
Sep 28, 2026	KURA Kura Oncology, Inc.	Sale(S)	12,448	$10.50	$130,670	Direct
Jun 18, 2026	KURA Kura Oncology, Inc.	Sale(S)	84,929	$9.82	$834,283	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	951	$8.46	$8,046	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	3,655	$8.46	$30,924	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	2,233	$8.46	$18,893	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	1,341	$8.46	$11,346	Direct
Jan 2, 2026	KURA Kura Oncology, Inc.	Award(A)	50,000	-	$0	Direct
Nov 14, 2025	KURA Kura Oncology, Inc.	Sale(S)	15,485	$11.18	$173,074	Direct
Nov 13, 2025	KURA Kura Oncology, Inc.	Award(A)	82,500	-	-	Direct
Sep 29, 2025	KURA Kura Oncology, Inc.	Sale(S)	12,314	$8.94	$110,114	Direct
Sep 27, 2025	KURA Kura Oncology, Inc.	Award(A)	82,500	-	-	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	2,253	$7.87	$17,735	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	816	$7.87	$6,423	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	1,353	$7.87	$10,651	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	541	$7.87	$4,259	Direct
Jan 2, 2025	KURA Kura Oncology, Inc.	Award(A)	46,250	-	$0	Direct

1-17 of 17 transactions

About Leoni Mollie

Leoni Mollie (SEC CIK 0002051106) files insider reports with the SEC as Chief Medical Officer of Kura Oncology, Inc. (KURA).

Signal8 holds 9 ownership filings by Leoni Mollie (1 Form 3, 8 Form 4), filed between Jan 7, 2025 and Sep 29, 2026. Those filings report 17 transactions, from Jan 2, 2025 to Sep 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Leoni Mollie's filings is in SAN DIEGO, CA.

Recent filings by Leoni Mollie

Sep 29, 2026: Open-market sale of KURA shares (Form 4, code S).
Sep 28, 2026: Open-market sale of KURA shares (Form 4, code S).
Jun 18, 2026: Open-market sale of KURA shares (Form 4, code S).
Jan 27, 2026: Open-market sales of KURA shares (4 lines, Form 4, code S).
Jan 2, 2026: Grant or award of KURA shares (Form 4, code A).

Other insiders filing for Kura Oncology, Inc. (KURA)

Bair Teresa Brophy, Chief Legal Officer
FORD KATHLEEN, Chief Operating Officer
DOYLE THOMAS JAMES, SVP, Finance & Accounting
Powl Brian T., Chief Commercial Officer
Burrows Francis, Chief Scientific Officer
Fulk Jennifer, Chief Financial Officer

How to read Form 4 transaction codes